What is Nektar Therapeutics?
Nektar Therapeutics is a biopharmaceutical company dedicated to the research and development of novel medicines. Leveraging expertise in advanced drug design and polymer conjugate technology, the company focuses on enhancing the therapeutic efficacy and safety of its compounds. Its primary areas of concentration include immunology, oncology, and autoimmune diseases, with a strategic objective to develop treatments that precisely modulate the immune system for durable patient benefit. Through a combination of internal research initiatives and strategic partnerships, Nektar Therapeutics endeavors to translate scientific discoveries into impactful therapies that improve patient outcomes.
How much funding has Nektar Therapeutics raised?
Nektar Therapeutics has raised a total of $2.2B across 14 funding rounds:
Debt
$125M
Corporate Investment
$25M
Stock Offering
$117M
Debt
$250M
Corporate Investment
$20M
Stock Offering
$175.5M
Share Placement
$850M
Share Placement
$30M
Debt (2012): $125M led by Undisclosed
Corporate Investment (2013): $25M supported by AstraZeneca
Stock Issuance/Offering (2014): $117M featuring Undisclosed
Debt (2015): $250M backed by TPG Special Situations Partners
Corporate Investment (2016): $20M with participation from Daiichi Sankyo
Stock Issuance/Offering (2016): $175.5M led by Undisclosed
Share Placement (2018): $850M supported by Bristol-Myers Squibb
Share Placement (2024): $30M, investors not publicly disclosed
Key Investors in Nektar Therapeutics
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical organization focused on discovering, developing, and manufacturing prescription medications for serious patient needs across oncology, cardiovascular disease, immunoscience, and virology. They invest heavily in research and development to create innovative treatments.
TPG Special Situations Partners
TPG Special Situations Partners is an investment entity that likely provides capital for companies requiring specialized financial solutions, potentially focusing on complex or transitional business phases.
AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
What's next for Nektar Therapeutics?
The recent major strategic investment in Nektar Therapeutics signals a pivotal phase for the company, likely enabling accelerated development of its drug candidates and expansion of its clinical trial programs. This capital infusion is expected to bolster its research and development capabilities, particularly in its core focus areas of oncology and immunology. The company's continued pursuit of innovative therapies suggests a forward-looking strategy aimed at addressing critical gaps in patient care and solidifying its market position within the competitive biopharmaceutical landscape. Future growth will likely be driven by successful clinical outcomes and strategic collaborations that leverage its proprietary technology platforms.
See full Nektar Therapeutics company page
